Sánchez-Salmón A, Barandela J, Garrido M, Ciobotaru A B, Albo C, Ruibal A
Servicio de Medicina Nuclear, Complejo Hospitalario Universitario, Santiago de Compostela, La Coruña, Spain.
Rev Esp Med Nucl. 2007 May-Jun;26(3):165-8. doi: 10.1157/13102487.
Positron Emission Tomography (PET) has become a very useful tool for monitoring Hodgkin's disease patients in the last years. When there is suspicion of disease persistence after treatment, this technique makes it possible to evaluate treatment activity of the residual lesions observed in the CT scan. Furthermore, due to the whole body study, new tumor sites, which very often change the therapeutic option, can be detected. We must take into account, however, that 18F-FDG is a very sensitive but not very specific tumor marker, since some inflammatory or infectious conditions may be associated to significant radiopharmaceutical uptakes. Thus, in order to increase specificity it is mandatory to correlate the PET information with the rest of the conventional imaging and clinical data and evolution of the patient. We present the case of a woman with Hodgkin's disease in which 18F-FDG PET was included in the follow-up. Both conditions, tumor and infection, were present in different times of the course. The integration of all the x-ray, clinical, laboratory and metabolic information allowed for a better and correct management of this patient.
正电子发射断层扫描（PET）在过去几年已成为监测霍奇金病患者的一项非常有用的工具。当怀疑治疗后疾病持续存在时，这项技术能够评估在CT扫描中观察到的残留病灶的治疗活性。此外，由于进行全身检查，可以检测到新的肿瘤部位，而这些部位常常会改变治疗方案。然而，我们必须考虑到，18F-FDG是一种非常敏感但特异性不强的肿瘤标志物，因为一些炎症或感染性疾病可能与显著的放射性药物摄取有关。因此，为了提高特异性，必须将PET信息与其他传统影像学、临床数据以及患者的病情进展相关联。我们介绍了一例霍奇金病女性患者，其随访过程中进行了18F-FDG PET检查。在病程的不同阶段，肿瘤和感染两种情况均有出现。综合所有的X线、临床、实验室和代谢信息，有助于对该患者进行更好、更正确的管理。
